What Alfatrim Treats: Main Uses and Benefits

The core therapeutic purpose of Alfatrim plays a role in managing symptoms in conditions involving active bacterial infection. The product is indicated for managing diseases caused by susceptible Gram-positive and Gram-negative organisms in cattle and pigs.

---

Key Therapeutic Applications

Alfatrim is generally used to provide therapeutic support in managing conditions presenting with systemic or localized discomfort, such as systemic imbalance associated with bacterial infection, pneumonia, colibacillosis, and metritis. This application is considered relevant for easing symptom clusters that may become intense or disruptive in major organ systems.

It is also applied in situations involving certain distressing symptoms linked to organ-specific functional stress, specifically in cases of septic arthritis, mastitis, and pododermatitis. In these contexts, the medication may assist with managing widespread symptoms like fever and pronounced lethargy, while also helping to reduce localized signs such as pain, swelling, and symptoms that interfere with daily functioning. This support contributes to improved comfort by easing the symptoms related to physical discomfort.

“The medication is commonly used when short-term symptomatic assistance is needed across several organ systems, supporting patients during difficult episodes by easing distress.”

Quick Fact: Relief for Acute Discomfort
Alfatrim is relevant in clinical settings that involve acute or unstable symptom patterns, especially when manifestations like labored breathing or disruptive diarrhea interfere with daily functioning.

The eligibility profile for the veterinary medicinal product Alfatrim (Sulfadiazine, Trimethoprim) is strictly defined by regulatory authorities based on species, pre-existing health status, and physiological state.

Approved and Prohibited Species

Alfatrim solution for injection is approved for use only in its established Target Species of Cattle and Pigs. The medicine is explicitly contraindicated and not for use in non-target species, including Horses and Sheep, as specified in the official regulatory documents.

Absolute Contraindications

Use of Alfatrim is strictly contraindicated in any animal with a known sulphonamide sensitivity or hypersensitivity to the active ingredients. The product must not be administered to animals diagnosed with severe organ dysfunction, including severe liver parenchymal damage or severe kidney disease (renal damage). Additionally, animals with existing blood dyscrasias (disorders of the blood components) are prohibited from receiving this medication.

Conditional Eligibility and Restrictions

For certain populations, eligibility is conditional. Regulatory documents state that the safety of the product has not been established in animals intended for breeding. Furthermore, use during pregnancy and lactation requires a formal benefit-risk assessment by a veterinarian. In all cases, use of the product should be based on susceptibility testing of the isolated bacteria.

Alfatrim's official regulatory documentation defines specific interaction patterns with other medicinal products and chemical substances. These interactions primarily fall into categories of pharmacodynamic outcomes and mandated procedural constraints. The product’s interaction profile does not document specific cytochrome P450 enzyme-mediated or transporter-based pharmacokinetic interactions.

Official Interaction Restrictions

The following combinations are restricted or prohibited according to regulatory labeling:

• Co-Administration Prohibition: The product must not be administered concomitantly with coccidiostats or veterinary medicinal products containing sulfonamides, nor should it be associated with the substance Para-aminobenzoic acid (PABA).
• Species-Specific Contraindication: Co-administration with Alpha2-adrenoceptor agonists is specifically contraindicated in horses due to the risk of fatal arrhythmias.

Documented Pharmacodynamic Outcomes

The profile identifies two key pharmacodynamic effects:

• Antagonism: Local anaesthetics from the PABA ester group (e.g., procaine, tetracaine) are documented to locally inhibit the effect of sulfonamides.
• Reinforcement: The sulfonamide component is officially stated to potentiate anticoagulants action.

Administration Constraint

Due to compatibility requirements, the solution for injection must not be mixed with any other veterinary medicinal products.

Dual Blockade of Bacterial Metabolism

Alfatrim exerts its effect through a selective sequential blockade targeting two distinct enzymes within the bacterial folic acid synthesis pathway, which is necessary for microbial proliferation. Sulfadiazine acts first by competitively inhibiting Dihydropteroate Synthase (DHPS), while Trimethoprim follows by reversibly inhibiting Dihydrofolate Reductase (DHFR). This dual intervention causes a rapid and profound depletion of Tetrahydrofolic Acid (THF), the co-factor needed to build DNA and RNA.

---

Achieving Synergistic Bactericidal Effect

The combination achieves synergy, where the concurrent blockade is greater than the additive effect of the individual drugs, leading to potentiation. This metabolic collapse—the inability to synthesize genetic material—results in a definitive bactericidal effect, leading to the bactericidal loss of microbial viability. The mechanism is selective because host animal cells obtain folate from their diet, functionally bypassing the blocked synthesis pathway.

---

Mechanism Limitations and Resistance

The mechanism's functional scope is limited by bacterial resistance, which arises from genetic mutations leading to altered or overproduced target enzymes (DHPS/DHFR) that reduce the drugs' affinity. Furthermore, environmental folate or thymidine, found in pus or necrotic tissue, can be scavenged by the bacteria, functionally by passing the internal synthesis blockade.

Alfatrim is provided as a sterile solution intended solely for parenteral administration via injection. The required method of use is strictly governed by the species being treated and the official dose rate, which is based on the concentration of Sulfadiazine (200 mg/mL) and Trimethoprim (40 mg/mL).

Approved Administration Routes and Dosing

For the primary target species, including cattle and pigs, the medicine is typically administered via intramuscular (IM) injection, though a slow intravenous (IV) injection is an approved alternative. The standard dosing schedule requires administration once daily at a rate of 15 mg of total active ingredients per kilogram (kg) of body weight. This corresponds to a volume of 1 mL of the product per 16 kg body weight. Accurate determination of body weight is required for precise volume calculation.

Species-Specific Protocols and Duration

Use of the solution in smaller species, such as dogs and cats, necessitates a different protocol: the administration must strictly use the subcutaneous (SC) route and requires a higher dose rate of 30 mg of total active ingredients per kg of body weight. Regardless of the species, the general duration pattern is to continue the once-daily administration for two days following the observation of symptom resolution, but the treatment course is officially limited to a maximum of five consecutive days.

Procedural Constraints

There are specific procedural requirements tied to the administration. For instance, the volume delivered via intramuscular injection must not exceed 15 mL per site in cattle or 5 mL per site in pigs. If the intravenous route is used, the solution must be warmed to body temperature and delivered slowly.

Research evidence / Overview of Studies for Alfatrim

The research evidence available for the Sulfadiazine-Trimethoprim combination is drawn from clinical evaluations submitted to regulatory authorities, peer-reviewed scientific literature, and pharmacokinetic studies. This overview describes the research landscape for the conditions for which the medicine was studied, highlighting what has been studied and what remains uncertain, based on the findings reported by researchers.

---

Evidence for Systemic and Respiratory Bacterial Infections

Research exploring this combination was primarily conducted in Clinical Field Trials, often using designs similar to Randomized Controlled Trials (RCTs), and was studied for systemic and respiratory conditions in cattle and pigs. Researchers examined outcomes related to systemic or functional imbalance, including measurements of clinical status change and the assessment of mortality and physiological strain over the study period. The research base for this established use includes substantial data for regulatory review.

What remains uncertain in this research area is the documented variability in the achievement of the optimal synergistic drug concentration ratio in the plasma of some species. Additionally, the clinical environment is subject to the limitation of increasing bacterial resistance to the antimicrobial class.

---

Evidence for Localized, Joint, and Reproductive Infections

The evidence base for localized infections, such as mastitis, metritis, and septic arthritis, relies on Clinical Field Trials and established Bibliographical Data that describes the interaction with bacterial components. Studies explored conditions associated with acute or disruptive episodes and examined outcomes related to physical discomfort and inflammatory or irritative states. The research base for this established use includes field data sufficient for regulatory review.

There is limited information for long-term outcomes regarding research scenarios involving chronic infection where the environment contains large volumes of pus or necrotic tissue, as data show patterns related to reduced effectiveness in purulent or chronic environments. The research context is also influenced by the documented concern of increasing bacterial resistance to the drug class.

Key Studies & References

1. Censutrim 200 mg/ml + 40 mg/ml Solution for Injection for Cattle, Pigs, Horses, Dogs and Cats - United Kingdom Veterinary Medicines Directorate Publicly Available Assessment Report
2. A comparison of some of the pharmacokinetic parameters of three commercial sulphadiazine/trimethoprim combined preparations given orally to pigs (PubMed ID: 2247946)

How to Store and Dispose of Alfatrim

The Alfatrim (Sulfadiazine and Trimethoprim Solution for Injection) must be stored in accordance with official regulatory requirements to ensure its stability.

Storage Requirements

The product must not be stored above 25 C and must not be frozen. To maintain protection, the container should be kept in the outer carton to protect from light. The product's shelf life is significantly reduced after the vial is first opened, being limited to 4 weeks (28 days). Like all medicines, it must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Alfatrim must not be disposed of via wastewater or household waste. Disposal must utilize take-back schemes or national collection systems in accordance with local environmental regulations.